BioSpace News Archive

BD, a leading global medical technology company, reported quarterly revenues of $4.9 billion for the third fiscal quarter ended June 30, 2021.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that its majority-owned company Oravax Medical Inc.'s oral COVID-19 vaccine will be featured in the Keynote Talk at the Arena International Vaccines Virtual Conference 2021 on August 5, 2021, at 9:00 a.m. Eastern.

Madrigal Pharmaceuticals, Inc. reports its second quarter 2021 financial results and provides a summary of corporate accomplishments.

The concept of laboratory automation is gaining decent traction as the organizations engaged in this field are growing interest toward capitalizing and optimizing diverse technologies in their laboratories.

The global diabetic foot ulcers and pressure ulcers market depicts the presence of few market players, says Transparency Market Research on the basis of a recently published report.

Inmagene Biopharmaceuticals and Kissei Pharmaceutical Co., Ltd. announced that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong and Macau.

Second quarter net sales of $1,067 million increased 117.3%, compared to $491 million in the second quarter of 2020.

Regeneron Pharmaceuticals, Inc. and Sanofi announced the Phase 3 trial of PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival primary endpoint in patients with advanced non-small cell lung cancer.

Arch Biopartners Inc., a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide is ongoing and will be disclosed to the public following third-party, scientific peer review.